Board of Directors Biographies
HOWARD PIEN, Chairman of the Board
Howard has worked in the pharmaceutical and biotechnology industries for more than 30 years. He is
currently a Board Director of the development-stage biopharmaceuticals companies: Bellerophon,
Immunogen, Juno and Sage; Vanda, a commercial-stage public company specializing in the central
nervous system (four years as Chairman); as well as the Chairman designee of Reckitt Benckiser
Pharmaceuticals. He is an advisor to the Life Sciences Practice of Warburg Pincus, a private equity firm.
Howard’s non-profit Board appointments include the Biotech Industry Organization, the Pharmaceutical
Research and Manufacturers of America, the Oakland Children’s Hospital and the Fox Chase Hospital.
From 2007 to 2009, Howard was the Chairman and Chief Executive Officer (CEO) of Medarex, Inc., a
public biotechnology company, until it was acquired by Bristol-Myers Squibb. From 2003 to 2006, he
was the Chairman and CEO of Chiron, a public biotechnology company, which was acquired by Novartis.
His previous Board directorships include Talon, Arresto, Ikaria and Biopharma (where he was lead
independent director). Between 1991 and 2003, he held various executive positions at GlaxoSmithKline
plc (GSK) and SmithKline Beecham, as Presidents of US, International and Pharmaceuticals. Prior to GSK,
Howard worked for Abbott Labs for six years and Merck & Co., Inc., for five years.
Howard graduated from MIT with a BS in engineering and from Carnegie-Mellon University with an
MBA.
SHAUN THAXTER, Board Member
Shaun was appointed Chief Executive Officer of Reckitt Benckiser Pharmaceuticals (RBP) in 2009 with a
remit to build a global company through the acquisition of the global marketing rights from Merck &
Co., and he ensured its successful integration to accelerate RBP towards its vision. He has spearheaded
the successful growth and development of RBP since launching the U.S. SUBOXONE® business in 2003.
Following his formal appointment as President of RBP in 2005, Shaun has led the company through
sustained growth, building a life cycle management pipeline and expanded addiction franchise that grew
from zero to a peak of $1.5 billion net revenue. Today, RBP successfully operates in 46 countries around
the world.
Shaun joined Reckitt & Colman in 1995 as Senior Brand Manager and advanced to Category Manager
within the company’s UK Healthcare business. Following the 1999 merger with Benckiser, he was
appointed Global Category Manager for the prescription product portfolio. Shaun graduated from Kings
College, London with a Joint Honors BSc in Biochemistry and Physiology and undertook his early career
with Proctor & Gamble and London International Group.
CARY CLAIBORNE, Board Member
Cary was appointed Chief Financial Officer (CFO) of Indivior in November 2014. Previously, Cary had
been the CFO of Sucampo Pharmaceuticals, Inc., a public global biopharmaceutical company focused on
1
discovery, development and commercialization, from 2011 to 2014. From 2009 to 2010, Cary was
President, Chief Executive Officer (CEO) and a member of the board of directors of New Generation
Biofuels, Inc., a public biofuel technology company, as well as its CFO from 2007 to 2009. From 2004 to
2007, Cary was CFO of Osiris Therapeutics, Inc., a public stem cell therapeutics company, leading the
company’s initial public offering in 2006. From 2001 to 2004, he was Vice President of Constellation
Energy Group, a diversified energy company. From 2000 to 2001, he was Vice President of The Home
Depot, Inc. Prior to Home Depot, Cary worked for MCI Corporation for three years.
Cary spent the first 15 years of his career in a series of progressively more responsible positions in
financial management and senior management, including President and CEO of New Enterprise
Wholesale Services at GE Capital and GE since 1982. Cary is also a member of the board of directors of
MedicAlert Foundation, where he serves as the Chairman of its Finance Committee. Cary graduated
from Rutgers University with a BA in Business Administration and from Villanova University with a MBA.
RUPERT BONDY, Board Member
Rupert joined energy company BP in 2008 as Group General Counsel, with worldwide responsibility for
legal and compliance matters. He is a member of the English Bar and the California Bar as well as various
professional bodies and committees.
Rupert began his career as a lawyer in private practice. In 1989, he joined U.S. law firm Morrison &
Foerster, working in San Francisco and London, and from 1994, he worked for UK law firm Lovells in
London. In 1995, he joined SmithKline Beecham as Senior Counsel for mergers and acquisitions and
other corporate matters. He subsequently held positions of increasing responsibility and following the
merger of SmithKline Beecham and Glaxo Wellcome to form GlaxoSmithKline in 2001, he was appointed
Senior Vice President and General Counsel.
Rupert obtained his undergraduate degree from Kings College, Cambridge, and was then a Harkness
fellow for a year at Harvard University. He also spent a year as a teaching fellow at Stanford Law School,
where he obtained a law degree.
YVONNE GREENSTREET, MBChB, MBA, Board Member
Yvonne has more than 20 years of global experience in the pharmaceutical industry, spanning research
and development, strategy and commercial development. Yvonne serves on the boards of directors of
Pacira Pharmaceuticals and Advanced Accelerator Applications. She also is on the Advisory Board of the
Bill and Melinda Gates Foundation.
Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at
Pfizer and a member of the global executive team for the $16 billion Specialty Business with
accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience
and rare disease areas. Prior to Pfizer, she was at GlaxoSmithKline plc (GSK) for 18 years where she was
Senior Vice President and Chief of Strategy for Research and Development (R&D), serving on the
corporate executive investment committee. She was responsible for enabling strategy development and
execution to achieve GSK’s goal of delivering five to seven new medicines per year while reducing R&D
spend. Yvonne was previously in various positions of increasing responsibility at GSK, including Senior
Vice President for Medicine Development and Chief Medical Officer for Europe.
Yvonne trained as a physician and earned her medical degree from Leeds University in the UK and her
MBA from INSEAD, France. She was recognized by Fast Company as one of the 100 most creative people
in business in the U.S. in 2013 and by FierceBiotech as one of the top 10 women in Biotechnology in
2012.
ADRIAN HENNAH, Board Member
Adrian is Chief Finance Officer (CFO) of Reckitt Benckiser Group plc, which he joined in January 2013. He
also is a Non-executive Director of Reed Elsevier PLC and Reed Elsevier NV.
Adrian was CFO of Smith & Nephew Plc from June 2006 to December 2012. Prior to Smith & Nephew,
Adrian was CFO of Invensys Plc for four years and spent 18 years at GlaxoSmithKline plc, where he held a
number of senior management and financial roles. Earlier in his career, Adrian worked at PwC (then
Price Waterhouse) in both audit and consultancy.
Adrian has a law degree from Cambridge University and is a Sloan Fellow of the London Business School.
A. THOMAS MCLELLAN, PhD, Board Member
Tom has been a career researcher for 35 years with the Treatment Research Institute (which he cofounded in 1992) and the University of Pennsylvania. In his career, Tom has published more than 400
articles and chapters on addiction research. He has received several awards, including Life Achievement
Awards from the American, Swedish, Italian and British Societies of Addiction Medicine and from the
American Public Health Association (2010).
From 2009 to 2011, Tom was unanimously confirmed by the U.S. Senate to serve as Deputy Director of
the White House Office of National Drug Control Policy, where he was one of the principal authors of
the President’s National Drug Control Strategy.
Tom holds a BA from Colgate University as well as an MS and PhD from Bryn Mawr College. He received
postgraduate training in Psychology at Oxford University in England.
LORNA PARKER, Board Member
Lorna is a senior adviser at BC Partners, a leading private equity firm. As an independent consultant, she
conducts board effectiveness reviews for UK public companies.
Lorna has an active not-for-profit portfolio. She is a Trustee of the Royal Horticultural Society, a Director
of Future Academies, a Governor of Pimlico Academy, a Trustee of BC Partners Foundation and up until
recently was a Trustee of Place2Be.
Lorna’s executive career was primarily in executive recruitment, as a partner at Spencer Stuart. Lorna
created and led the company’s private equity practice across Europe, co-led the legal search practice
globally, was a member of the UK board practice and was managing director of the UK business. Prior to
joining Spencer Stuart, Lorna worked for Advent (venture capital) and Kleinwort Benson (investment
bank).
Lorna has an MA in Economics from Cambridge University and MBA from Stanford Business School,
where she was a Harkness Fellow.
DANIEL J. PHELAN, Board Member
Dan is a Board Director of TE Connectivity (formerly Tyco Electronics) and serves on the Management
Development & Compensation Committee. He is a member of the Health Care and Life Sciences
Advisory Board of Computer Sciences Corporation and the Advisory Board of RiseSmart. He also is an
Executive Director of Executive Networks and is a member of the Board of Trustees of Rutgers
University.
Dan retired from GlaxoSmithKline plc in December 2012 after 31 years, during which he was an advisor
to three chief executives and was a member of the Corporate Executive Team. Prior to his retirement,
he was Chief of Staff with global responsibility for Corporate Strategy and Development, Human
Resources, Information Technology, Real Estate and Facilities, Environmental Health and Safety, and
Security. Before that, he was Senior Vice President, Human Resources for 14 years. Dan is a graduate of
Rutgers College. He holds an MS degree from The Ohio State University and a law degree from Rutgers
University School of Law. He is admitted to practice in New Jersey and Pennsylvania.
Dan served as an officer on active duty and in the U.S. Army Medical Service Corps reserve. He has
published on Chief Executive Officer succession planning and on boarding and public sector collective
bargaining.
CHRISTIAN S. SCHADE, Board Member
Chris is Chief Executive Officer of Novira Therapeutics Inc., a privately held biopharmaceutical company.
He is a Board Director of Integra Life Sciences and a member of its Audit Committee and Chair of its
Finance Committee. Chris also chairs the Board of Trustees at Princeton Academy School.
Chris was previously Executive Vice President (EVP) and Chief Financial Officer (CFO) of Omthera
Pharmaceuticals, Inc., a specialty pharmaceutical company, prior to its disposal in July 2013 to
AstraZeneca for potentially up to $445 million. He was EVP and CFO at NRG Energy from March 2010 to
September 2011. Chris joined Medarex Inc., in 2000 and helped it grow to become a leading
pharmaceutical development company and, as Senior Vice President Administration and CFO, played a
lead role in the negotiations for Bristol-Myers Squibb Co.’s $2.4 billion acquisition of Medarex in
September 2009 and the subsequent merger-integration process.
Prior to Medarex, Chris served as Managing Director and head of the European Corporate Funding
Group at Merrill Lynch in London and also held various capital markets and corporate finance positions
in New York and London for both Merrill Lynch and JP Morgan Chase & Co.
DANIEL TASSÉ, Board Member
Daniel is Chairman and Chief Executive Officer (CEO) of Ikaria, Inc., and a Director of Bellerophon
Therapeutics. He has served as Ikaria’s President and CEO since 2008 and was appointed Chairman of
the Board of Directors in October 2009. Daniel oversaw the spinoff of Bellerophon Therapeutics from
Ikaria in 2013, creating two companies to best leverage the scientific, financial and marketing strengths
of the company.
Daniel is a member of the Healthcare Leadership Council, a Board Director of the Roundtable on Critical
Care Policy and Chairman of the Foundation on National Critical Care Policy. He also is a member of the
Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization,
where he participates on the bioethics, regulatory environment and reimbursement committees, and a
Board Director of PhRMA, where he participates on the U.S. Food and Drug Administration and
Biomedical Research Committee.
Prior to joining Ikaria, Daniel served as General Manager of the Pharmaceuticals and Technologies
Business Unit of Baxter International. Earlier in his career, he held a number of senior management
positions at GlaxoSmithKline (GSK); from 2001 to 2004, he was Vice President and Regional Director for
Australasia at GSK.
Daniel holds a BSc in Biochemistry from the University of Montreal.
LOLA EMETULU , Company Secretary
Lola Emetulu is a Fellow of the Institute of Chartered Secretaries and Administrators and a Solicitor of
the Supreme Court of England & Wales with 20 years’ experience in governance and compliance
matters. She started her career as a company secretary in the Corporate Law Department of the law
firm Linklaters. She moved to Vodafone in 2002, where she completed her solicitor’s qualifications and
subsequently joined Kingfisher plc in 2008 as deputy company secretary. Lola has been deputy company
secretary and corporate solicitor at RB since 2010.